InvestorsHub Logo
Followers 14
Posts 1044
Boards Moderated 0
Alias Born 02/28/2017

Re: Renegades17 post# 2967

Friday, 02/01/2019 4:13:43 PM

Friday, February 01, 2019 4:13:43 PM

Post# of 3854
I don't know if I would say that it's been underwhelming... Honestly I think the friedland thing hurt here too.. That said this team really has rallied and being a start up biopharma organization I have learned patience. Product selling is years off... but that doesn't mean orphan drug study or clinical phase advancements are. I do believe things like which IVY University will be announced after the cross listing.

With that said NXEN did reply to my inquiry on CSE cross listing with "Our cross listing on the CSE continues to follow its due course." They went on to mention that the listing involves CSE and OSC involvement which they have no control over. It sounds like they are continuing to pursue the listing and that it's just a matter of time and patience while the agencies do their thing. Can't ask for more than that.

I believe a cross-listing will help drive interest and investments which will allow the company access to more capital when they are ready which can be used to accelerate clinical studies and product development.

I am still interested in the orphan drug study proposal request update at some point.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NXEN News